Acetylon Pharmaceuticals, Inc.

Acetylon Pharmaceuticals is pursuing development of next-generation, selective histone deacetylase (HDAC) enzyme inhibitors with potential for treatment of hematologic and solid tumor cancers, inflammatory diseases such as rheumatoid arthritis, neurodegenerative diseases such as Parkinson's, genetic diseases incluidng sickle cell disease and thalassemia major, and infectious disease such as malaria. Acetylon's technology is being licensed from Harvard University and the Dana Farber Cancer Center. Acetylon raised $7.25M in a Series A finanicng involving private investors including The Kraft Group in July 2009.